MESO Mesoblast Ltd

Price (delayed)

$15.29

Market cap

$1.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.44

Enterprise value

$1.89B

?
Relative Growth: Rel. Growth: 55
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 42

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its ...

Highlights
The EPS has increased by 48% YoY
Mesoblast's net income has increased by 44% YoY
The debt is up by 29% year-on-year
Mesoblast's equity has decreased by 4.9% YoY

Key stats

What are the main financial stats of MESO

MESO stock price

How has the Mesoblast stock price performed over time
Intraday
-3.96%
1 week
6.11%
1 month
-10.06%
1 year
-6.25%
YTD
-15.24%
QTD
13.01%

Financial performance

How have Mesoblast's revenue and profit performed over time
Revenue
$120.25M
Gross profit
$120.25M
Operating income
-$29.3M
Net income
-$57.5M
Gross margin
100%
Net margin
-47.8%
The operating margin has surged by 92% year-on-year
The net margin has surged by 92% year-on-year
MESO's operating income is up by 46% year-on-year
Mesoblast's net income has increased by 44% YoY

Price vs fundamentals

How does MESO's price correlate with its fundamentals

Growth

What is Mesoblast's growth rate over time

Valuation

What is Mesoblast stock price valuation
P/E
N/A
P/B
3.47
P/S
16.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.7
The EPS has increased by 48% YoY
Mesoblast's equity has decreased by 4.9% YoY

Efficiency

How efficient is Mesoblast business performance
The ROS has soared by 94% YoY
The ROA has grown by 48% YoY
MESO's ROE is up by 48% year-on-year

Dividends

What is MESO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MESO.

Financial health

How did Mesoblast financials performed over time
MESO's current ratio is up by 22% year-on-year
The quick ratio rose by 15% YoY
The debt is 99% smaller than the equity
The debt is up by 29% year-on-year
Mesoblast's equity has decreased by 4.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.